EMA ERA Decision Tree & Navigator
Interactive decision-support tool for navigating Phase I and PBT/vPvB ERA pathways.
ToxWriter provides project-focused pharmaceutical Environmental Risk Assessment (ERA) services for human medicinal products, alongside PDE / ADE, OEL / OEB and regulatory toxicology support. The assessment pathway is adapted to the active substance, product, intended market and available evidence.
Clear toxicological reasoning, regulatory context and disciplined documentation across environmental and human-health exposure questions.
Assessment of environmental exposure and potential risk from the use of human medicinal products, structured around the current regulatory framework and the active substance.
PDEHealth-based exposure limit assessments that review pharmacology, toxicology, critical effects, points of departure and uncertainty considerations.
OELOccupational exposure assessments focused on worker protection, airborne exposure limits, exposure bands and the link between toxicology and industrial hygiene.
ToxWriter supports pharmaceutical ERA from initial exposure screening through Phase II, environmental risk characterisation and relevant PBT/vPvB assessment. The work is aligned to the intended regulatory market and the evidence available for the active substance.
Review the active substance, use context, maximum daily dose and relevant exposure inputs, including PECSW and FPEN considerations.
PHASE IIWhere triggered, support environmental fate and ecotoxicity evaluation and PEC/PNEC-based risk characterisation.
PBTAssess relevant persistence, bioaccumulation and toxicity considerations and identify environmental data and access requirements for the submission.
Looking for a substance that is not yet listed? ToxWriter can also review custom ERA requirements for active substances outside the profile directory. Discuss your substance →
Substance, product, route, intended market and submission context are established before scope is fixed.
Available regulatory, literature, pharmacological, toxicological and environmental evidence is evaluated for relevance and reliability.
The agreed assessment is translated into structured scientific documentation with clear rationale and traceable scope.
Search the active-substance ERA directory. Profile pages do not publish confidential study results or report files.
Search the PDE / ADE profile directory and request project-specific scope and applicability.
Search the occupational exposure profile directory and request project-specific support.
Explore regulatory concepts before requesting a project-specific assessment. These pages are written as general background and link to the relevant official guidance.
Interactive decision-support tool for navigating Phase I and PBT/vPvB ERA pathways.
How the environmental assessment progresses from environmental exposure screening to further fate, effects and risk characterisation.
How the current EMA framework relates to UK ERA submissions and UK prevalence considerations.
Why population fraction and treatment context can affect the Phase I environmental exposure estimate.
How a health-based exposure limit is derived from pharmacology, toxicology, a point of departure and adjustment factors.
How workplace exposure limits and exposure bands fit into occupational risk management.
A practical comparison of three distinct regulatory and occupational exposure concepts.
We will review the requested scope and confirm the appropriate assessment pathway, information needs and next step.